Results 11 to 20 of about 22,545,234 (252)
Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients [PDF]
Salma M AlDallal Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro ...
AlDallal SM
doaj +2 more sources
Background Evidence suggests that monoclonal B-cell lymphocytosis precedes all chronic lymphocytic leukemia cases, although the molecular mechanisms responsible for disease progression are not understood.
Felipe Magalhães Furtado +7 more
doaj +2 more sources
Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia [PDF]
The aim of this multicenter GIMEMA study was to correlate autoimmune complications (AIC) in B-cell chronic lymphocytic leukemia (B-CLL) with stage and therapy.
W Barcellini +14 more
doaj +2 more sources
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas [PDF]
Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medicine, 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, 3Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic,
Madanat YF, Smith MR, Almasan A, Hill BT
doaj +1 more source
Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19+, CD5+ and CD23+.
Celso Arrais Rodrigues +14 more
doaj +3 more sources
Expression of CD95, a molecule involved in activation-induced cell death (AICD), might contribute to explain accumulation of leukemic B-cells and functional impairment of T-cells in B-cell chronic lymphocytic leukemia (B-CLL).
U De Fanis +5 more
doaj +1 more source
Expressió de ZAP-70 en linfòcits B normals i síndromes limfoproliferatives B [PDF]
[cat] La Leucèmia Limfàtica Crònica (LLC), la més freqüent de les leucèmies en el món occidental, és una malaltia produïda per la proliferació i cúmul de limfòcits B madurs, actualment incurable.
Crespo Maull, Marta
core +3 more sources
Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6 [PDF]
The authors acknowledge TENOVUS Tayside for funding the studyTenovin-6 (Tnv-6) is a bioactive small molecule with anti-neoplastic activity. Inhibition of the Sirtuin class of protein deacetylases with activation of p53 function is associated with the pro-
Coates, Philip J. +44 more
core +1 more source
Cytoplasmic immunoglobulins in chronic lymphocytic leukemia B cells [PDF]
It is generally assumed that chronic lymphocytic leukemia of B cell origin (B-CLL) is characterized by the presence of surface membrane immunoglobulins (SmIg) and by the absence of cytoplasmic immunoglobulins (CyIg). In a variable number of cases SmIg are not detectable because of their low density on the cellular surface.
G, Pianezze +4 more
openaire +3 more sources
Background The malignant B cells in chronic lymphocytic leukemia receive signals from the bone marrow and lymph node microenvironments which regulate their survival and proliferation. Characterization of these signals and the pathways that propagate them
Francisco de Paula Careta +9 more
doaj +1 more source

